NHS Dudley Health Economy Medicines Formulary
Home > 8 Malignant disease and immunosuppression > 8.2 Drugs affecting the immune response > 8.2.3 Anti-lymphocyte monoclonal antibodies > Chronic lymphocytic leukaemia - ofatumumab - NICE TAG TA202

Chronic lymphocytic leukaemia - ofatumumab - NICE TAG TA202

1.1 Ofatumumab is not recommended for the treatment of chronic lymphocytic leukaemia that is refractory to fludarabine and alemtuzumab.

1.2 People currently receiving ofatumumab for the treatment of chronic lymphocytic leukaemia that is refractory to fludarabine and alemtuzumab should have the option to continue treatment until they and their clinician consider it appropriate to stop.

https://www.nice.org.uk/guidance/TA202

Site by Devopa
© Copyright 2020 NHS. All rights reserved.